Attached files

file filename
EX-99 - PRESS RELEASE - XBiotech Inc.newsrelease.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 26, 2015 


XBIOTECH INC.
(Exact name of registrant as specified in its charter)


British Columbia, Canada
(State of Incorporation)

001-37347
(Commission File Number)

N/A
(IRS Employer Identification No.)


8201 E Riverside Dr. Bldg 4, Ste 100
Austin, Texas
78744
(Address of principal executive offices) (Zip Code)

(512) 386-2900
(Registrant's telephone number, including area code)

________________________________________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    [   ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [   ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [   ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [   ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01. Other Events.

On May 26, 2015, XBiotech Inc. (the "Company"), announced that it has successfully isolated and cloned an anti-Ebola product candidate using its True Human antibody discovery platform. The antibody was derived from a previously disclosed blood donation received earlier this year from a patient who recovered from Ebola. A copy of the Company's press release announcing the foregoing is attached as Exhibit 99.1 and is incorporated herein by reference.

The "Risk Factors" section of our prospectus filed with the Securities and Exchange Commission on April 16, 2015 discusses risks related to our Ebola research and possible biologic drug development. Those risk factors are incorporated herein by reference.

This Form 8-K and the related press release contains forward-looking statements, including declarations regarding management's beliefs and expectations, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosure set forth in "Risk Factors" in our SEC filings

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of XBiotech Inc., issued May 26, 2015


SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    XBIOTECH INC.
(Registrant)


May 29, 2015
(Date)
  /s/   JOHN SIMARD
John Simard
Chief Executive Officer and President

EXHIBIT INDEX

Exhibit
Number


Description

99.1

Press Release, issued May 26, 2015